https://accedacris.ulpgc.es/jspui/handle/10553/30002 2026-05-14T04:32:31Z 2026-05-14T04:32:31Z Mies Padilla, Sergio Rodríguez Suárez, Claudio Alberto Infante-Guedes, Aday González De La Torre, Héctor https://accedacris.ulpgc.es/jspui/handle/10553/165871 2026-05-13T17:24:32Z 2026-01-01T00:00:00Z

Título: Effectiveness of Gamification with a Narrative Adapted to the Player’s Profile in Obstetric Nursing Competencies: A Cluster Randomized Controlled Pilot Trial Protocol Autores/as: Mies Padilla, Sergio; Rodríguez Suárez, Claudio Alberto; Infante-Guedes, Aday; González De La Torre, Héctor Resumen: Background/Objectives: Simulation-based education often lacks personalization, focusing on technical competence rather than individual student profiles. This protocol describes a study designed to evaluate whether adapting gamified narratives to nursing students’ personality profiles has the potential to support academic performance in obstetrics. This study aims to validate the integration of psychometric profiling and AI as a sustainable strategy for personalized clinical training. Methods: A cluster-randomized controlled longitudinal pilot trial will be conducted at the University of Atlántico Medio. The protocol has been submitted for registration at ClinicalTrials.gov (Registration Pending). Thirty-eight second-year nursing students meeting inclusion criteria (excluding repeaters or those with prior specialized training) will be assigned by natural practice to either a control group (generic gamification) or an experimental group (gamification adapted according to Player Personality and Dynamics Scale profiles using AI-generated content). The intervention comprises four clinical simulation sessions focusing on pregnancy and childbirth, which are managed via the Wix platform. The primary outcome is academic performance, measured as “Learning Gain” (post-test scores minus pre-test scores). Secondary outcomes include student satisfaction measured via the Gameful Experience Scale. Data will be analyzed using Mann–Whitney U tests to compare overall efficacy and intragroup evolution. To minimize observer bias, knowledge assessments will utilize automated, objective scoring, and participants will be blinded to the study hypothesis. Expected Outcomes: The study aims to establish the technical and pedagogical feasibility of integrating AI-adapted narratives into nursing curricula. It is anticipated that the personalized approach will show positive trends in learning gains and engagement patterns, providing a baseline for larger multicenter trials. Conclusions: This protocol presents a framework for “Precision Education” in nursing, shifting from “one-size-fits-all” simulations to student-centered adaptive training. The use of Generative AI makes such personalization sustainable and cost-effective for health science faculties.

2026-01-01T00:00:00Z Socinski, Mark A. Stahel, Rolf Lee, Dae Ho Cappuzzo, Federico Nishio, Makoto Lovly, Christine M. Ozyilkan, Ozgur Li, Qingshan Johnson, Melissa Garon, Edward B. Kilickap, Saadettin da Silva, Flavio Augusto Ferreira Alatorre-Alexander, Jorge Meng, Raymond Amin, Reena Matheny, Christina Troutman, Sarah Wen, Xiaohui Patil, Namrata S. Zou, Wei Rodríguez Abreu, Delvys https://accedacris.ulpgc.es/jspui/handle/10553/165870 2026-05-13T17:21:47Z 2026-01-01T00:00:00Z

Título: Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer Autores/as: Socinski, Mark A.; Stahel, Rolf; Lee, Dae Ho; Cappuzzo, Federico; Nishio, Makoto; Lovly, Christine M.; Ozyilkan, Ozgur; Li, Qingshan; Johnson, Melissa; Garon, Edward B.; Kilickap, Saadettin; da Silva, Flavio Augusto Ferreira; Alatorre-Alexander, Jorge; Meng, Raymond; Amin, Reena; Matheny, Christina; Troutman, Sarah; Wen, Xiaohui; Patil, Namrata S.; Zou, Wei; Rodríguez Abreu, Delvys Resumen: This randomized clinical trial evaluates the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous non-small cell lung cancer.QuestionCan treatment with the combination of tiragolumab plus atezolizumab plus chemotherapy improve outcomes for patients with advanced nonsquamous non-small cell lung cancer (NSCLC)?FindingsIn this phase 3 randomized clinical trial of 542 patients with previously untreated, locally advanced unresectable or metastatic NSCLC, tiragolumab plus atezolizumab plus chemotherapy did not demonstrate a progression-free or overall survival benefit vs placebo plus pembrolizumab plus chemotherapy. Tiragolumab plus atezolizumab plus chemotherapy demonstrated a safety profile that was generally similar to that of pembrolizumab plus chemotherapy.MeaningTreatment with the combination of tiragolumab plus atezolizumab plus chemotherapy did not improve outcomes for patients with advanced nonsquamous NSCLC compared with pembrolizumab plus chemotherapy.ImportanceProgrammed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression.ObjectiveTo evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC.Design, Setting, and ParticipantsSKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024).InterventionPatients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg/m2, and carboplatin [area under the curve 5], or cisplatin, 75 mg/m2) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent.Main Outcomes and MeasuresPrimary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated.ResultsOf 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57; P = .99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73; P = .98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively.Conclusions and RelevanceIn the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated.Trial RegistrationClinicalTrials.gov Identifier: NCT04619797

2026-01-01T00:00:00Z Maanen, Nicole van Ruiter, Marleen de Jäger, Wiebke Casartelli, Veronica Ciurean, Roxana Padrón Fumero, Noemi Daloz, Anne Sophie Geurts, David Gottardo, Stefania Hochrainer Stigler, Stefan López Díez, Abel Díaz Pacheco, Jaime Salvador Dorta Antequera, Pedro Febles Arévalo, Tamara Lucía García González, Sara Hernández Martín, Raúl Álvarez Albelo, Carmen Díaz Hernández, Juan José Lin Ma Monteleone, V Reiter, Karina Stolte, Tristian Šakić Trogrlić, Robert Torresan, Silvia Tatman, Sharon Romero Manrique de Lara, David Hernández González, Yeray Ward, Philip J. https://accedacris.ulpgc.es/jspui/handle/10553/165869 2026-05-13T16:15:51Z 2025-01-01T00:00:00Z

Título: Bridging science and practice on multi-hazard risk drivers: stakeholder insights from five pilot studies in Europe Autores/as: Maanen, Nicole van; Ruiter, Marleen de; Jäger, Wiebke; Casartelli, Veronica; Ciurean, Roxana; Padrón Fumero, Noemi; Daloz, Anne Sophie; Geurts, David; Gottardo, Stefania; Hochrainer Stigler, Stefan; López Díez, Abel; Díaz Pacheco, Jaime Salvador; Dorta Antequera, Pedro; Febles Arévalo, Tamara Lucía; García González, Sara; Hernández Martín, Raúl; Álvarez Albelo, Carmen; Díaz Hernández, Juan José; Lin Ma; Monteleone, V; Reiter, Karina; Stolte, Tristian; Šakić Trogrlić, Robert; Torresan, Silvia; Tatman, Sharon; Romero Manrique de Lara, David; Hernández González, Yeray; Ward, Philip J. Resumen: Effective disaster risk management requires approaches that account for multiple interacting hazards, dynamic vulnerabilities, and institutional complexity. Yet many existing risk assessment methods struggle to reflect how these risks evolve in practice. This paper explores multi-hazard risk dynamics through stakeholder interviews across five European regions (Veneto, Scandinavia, the North Sea, the Danube Region, and the Canary Islands). Stakeholders described how exposure and vulnerability shift over time due to climate change, urban development, and socio-economic dependencies. The interviews highlight governance challenges and the critical role of institutional coordination, as well as synergies and asynergies in DRR measures, where efforts to reduce one risk can unintentionally increase another. By foregrounding real-world experiences across diverse hazard landscapes and sectors, this study offers empirical insights into how multi-hazard risk is perceived and managed. It underscores the need for flexible, context-sensitive strategies that bridge scientific assessment with decision-making on the ground.

2025-01-01T00:00:00Z Febles Arévalo, Tamara Lucía Díaz Pacheco, Jaime Salvador Dorta Antequera, Pedro Martínez Quintana, Lucía López Díez, Abel https://accedacris.ulpgc.es/jspui/handle/10553/165868 2026-05-13T15:41:40Z 2026-01-01T00:00:00Z

Título: Integrating Disaster Risk Reduction and Climate Adaptation Across Regional, Island, and Municipal Levels: A Systemic Analysis in the Canary Islands Autores/as: Febles Arévalo, Tamara Lucía; Díaz Pacheco, Jaime Salvador; Dorta Antequera, Pedro; Martínez Quintana, Lucía; López Díez, Abel Resumen: Disaster risk reduction and management are essential for sustainable development in territories highly exposed and vulnerable to natural hazards. Recent disasters in the Canary Islands have highlighted the importance of proactive preparedness and systemic approaches to risk management, emphasizing the need to better understand existing barriers to disaster risk reduction (DRR). This study develops an analysis of risk governance within the current planning instruments in the Canary Islands, the island of Tenerife, and the municipality of Candelaria. The research examines the integration of DRR across strategic, territorial, urban, and emergency planning at the regional, insular, and municipal levels. The findings identify key challenges and opportunities for integrating DRR within existing planning frameworks, highlighting both the potential and the limitations of current instruments as cross-cutting tools for building more resilient territories. While Tenerife has a relatively solid administrative and planning structure that could support a more systemic vision of risk, sectoral fragmentation and coordination gaps remain. Overall, the study contributes to the ongoing discussion on advancing risk governance from a systemic perspective at the local level. The challenges identified delineate the boundaries and directions for improvement, offering a valuable contribution to the existing body of knowledge.

2026-01-01T00:00:00Z